Newsletter · · Ashutosh Agarwal

Biotech's Renaissance Meets a Wall of Patent Expirations as Lilly Keeps Shopping - Weekly Pharma / Biotech / Life Sciences Podcast Recap - Week of September 6, 2026

Weekly Pharma / Biotech / Life Sciences Podcast Recap for the week of August 30 to September 6, 2026. Podcast synthesis on the biotech rally the analysts are trying to explain, the White House most-favored-nation pricing deals landing softer than feared, Eli Lilly's thirteenth takeout of the year, and the roughly 500 billion dollar patent cliff driving the M&A wave.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of September 6, 2026: Biotech's Renaissance Meets a Wall of Patent Expirations as Lilly Keeps Shopping

A busy, upbeat week for the drug business on the podcast circuit. The single loudest message: after years in the doghouse, biotech and pharma stocks are having a genuine "renaissance," and the people who study these companies for a living are trying to figure out whether it has legs. Underneath that, three storylines kept coming up: the White House's drug-pricing deals, Eli Lilly's non-stop shopping spree, and the enormous "patent cliff" that is about to knock a wall of revenue off the biggest drugmakers.

Below is what the week's episodes actually said, with the specifics, the numbers, and the arguments on both sides.

1. Dominant themes

Theme 1, biotech is suddenly hot again, and everyone wants to know why. The clearest data point came from RBC Capital Markets' team on their own show, Pathfinders in Biopharma. Brian Abrams, RBC's head of global healthcare research, laid out the scoreboard: the XBI (the equal-weighted biotech index that traders use as the sector's thermometer) is up 80% in the past year, "and a lot of that has come since early June, which is actually what makes it so striking." What drove it? In his words, "you really have to start with M&A," companies buying each other. Cumulative deal value hit roughly $78 billion by mid-year, nearly double the entirety of 2025. On top of that, the FDA calmed down after a jittery start to the year, worries about drug pricing faded from the headlines, and money rotated out of expensive AI/tech names into cheaper healthcare.

UBS's senior pharma and biotech analyst Michael Yee put it even more plainly on Closing Bell Overtime: "the charts are starting to break out... we're having a renaissance." He even floated biotech as "a bit of the anti-AI trade," a place to hide if you are nervous about how expensive AI stocks have gotten.

Theme 2, the White House's "most favored nation" drug-pricing deals became real, and the industry mostly shrugged. "Most favored nation" (MFN) pricing means tying US drug prices to the lower prices other rich countries pay. For two years it was treated as an existential threat; this week it turned into a manageable reality. On BioCentury This Week, veteran policy journalist Steve Usdin reported that 17 companies had already signed MFN deals, and CNBC's Closing Bell reported nine more added the same day (Astellas, Teva, BridgeBio, BeOne/B1 Medicines among them), taking the total to 26. The deals mostly involve giving state Medicaid programs the lower international prices, in exchange for being spared 100% pharma import tariffs and mandatory Medicare pricing tests.

The investor takeaway, from Michael Yee: "importantly for investors this has removed a lot of overhang and uncertainty... because these are not dramatic overhauls, not going to dramatically change things that are important for investors." In other words, the market was relieved the deals were mild.

Theme 3, Eli Lilly's shopping spree and the state of the obesity-drug empire. Lilly bought yet another company, Merida, a Cambridge, Mass. autoimmune/allergy startup, for up to ~$2.9 billion ($2.875B, with the upfront undisclosed). BioCentury's Lindsay Martin noted this is "Lily's 13th takeout of the year," and that on acquisitions alone Lilly has spent "at least $31.5 billion in total... at least $22.6 billion in upfront payments" in 2026. Her colleague's dry reaction: "That's probably just a day's worth of sales."

Separately, Lilly CEO David Ricks (interviewed on Squawk on the Street from the G20) gave a state-of-the-union on the weight-loss business: about 65% of the company is now obesity/weight-loss/diabetes, the other 35% growing nicely. Three years into these drugs, "we probably have 25, 30 million people globally on them" against "more than a billion potential customers." The next legs of growth: the new oral pill (branded Foundeo, in plain English a GLP-1 you swallow instead of inject), a Medicare "Bridge" program opening access for seniors, and next-generation drugs retatrutide and aluralintide.

Theme 4, the "$500 billion patent cliff." An explainer episode on the Elon Musk Podcast (a general-interest show, despite the name) walked through the wave of blockbuster drugs about to lose patent protection: "over $500 billion in projected annual global drug sales... about to lose their exclusive patent protection," or "half of all currently marketed drugs." The poster child is Merck's cancer immunotherapy Keytruda, which "generates roughly $30 billion annually" and loses US exclusivity soon. Bristol-Myers Squibb faces its own double whammy, Opdivo and the blood thinner Eliquis (about $14 billion, ~30% of BMS revenue) expiring around the same time, "over 65% revenue exposure for each company." The episode made a useful distinction: small-molecule pills like Eliquis collapse "incredibly fast and incredibly violent" once generics hit, while complex biologics like Keytruda and Opdivo erode more slowly because biosimilar copies are harder to make. This patent cliff is exactly why big pharma is buying biotech so aggressively (Theme 1).

Theme 5, tariffs and "build it here." Commerce Secretary Howard Lutnick, on Bloomberg's Balance of Power, described the carrot-and-stick reshoring policy: "Build it here and you won't pay a tariff while you're building. But if you're not willing to put shovels in the ground here, then you should pay to have access to the greatest market in the world." He said the approach "has been very successful with pharmaceuticals." Lilly's Ricks confirmed the mechanism from the company side: "You're exempt because you have committed to both most favored nations and building in the U.S.," adding that the new 100% tariffs are really aimed at generics, "nine out of ten prescriptions Americans fill are generic and very cheap, but they're mostly sourced from overseas."

Theme 6, AI in drug discovery: real, but only with the right data and the right partner. The most substantive AI discussion came from Inceptive CEO Jakob Uszkoreit on Inside the ICE House, describing Inceptive's partnership with Alnylam. His argument: "AI's lifeblood is data... you need a ton, and you need data that speaks to the problems you're trying to solve." Because Alnylam spent 15+ years proving out RNA-interference medicines (in plain English, drugs that silence disease-causing genes), "every piece of data they've generated... is relevant training data." He also pushed back on the standard VC skepticism that "platform companies don't work," arguing the company most likely to build a second successful platform is one that already built a first. Separately, Pfizer CEO Albert Bourla's essay on reorganizing the company around AI was discussed on Sidecar Sync.

Theme 7, cancer drug readouts kept coming (mostly clinician-focused, but investor-relevant). A cluster of oncology podcasts detailed new trial data with clear company implications:

  • Multiple myeloma (a blood cancer): On Blood Cancer Talks, Dr. Prashant Kapoor reviewed J&J's teclistamab. In the MajesTEC-9 trial, teclistamab as a single drug hit 70% progression-free survival at 18 months vs. 27% for standard chemo (hazard ratio 0.29) in hard-to-treat patients. A parallel trial (Monumental-6) for J&J's talquetamab showed a similar hazard ratio (~0.27 to 0.29). The clinical debate: use these "bispecific" antibodies before or after CAR-T cell therapy (also J&J/Legend's cilta-cel), with Kapoor leaning bispecific-first because of CAR-T's rare but irreversible side effects like Parkinsonism.
  • Breast cancer: On Breast Cancer Update, the DESTINY-Breast09 trial put AstraZeneca/Daiichi's Enhertu (TDXd) plus pertuzumab ahead of standard chemo (~38-month median progression-free survival), and Pfizer's palbociclib in the PATINA trial hit 44-month median PFS, recently approved.
  • Lung/pancreatic cancer: On OncoPharm, Revolution Medicine's daraxonrasib (its RAS-targeting drug) was discussed in lung cancer alongside a dosing/toxicity trade-off.
  • New approval: Oncology Brothers covered the FDA approval of rusfertide for polycythemia vera (a blood disorder), based on the VERIFY trial.

Theme 8, cardiovascular readouts worth noting. Circulation on the Run covered AstraZeneca's heart-failure candidate AZD5462 (the Luminara trial), which showed a surprising "less-is-more" result, the lowest 20mg dose produced the most benefit (5.4 mL/m² of reverse cardiac remodeling), with higher doses working less well. The same episode covered aficamten (Cytokinetics' heart-muscle drug) in the ACACIA-HCM trial, where north of 70% of patients with non-obstructive hypertrophic cardiomyopathy improved on symptoms, the first therapy ever to help that specific group.

2. Active debates

Has biotech's rally gone too far? RBC's stance is "constructive but selective." As Brian Abrams put it: "The rally has been real, and the reasons for it have been legitimate. But... we don't think the sector has completely de-risked here." Their sentiment survey of 60+ investors, taken at the July peak, captured the mood shift: 58% still expect biotech to outperform the S&P 500 in the second half (only a record-low 8% expect underperformance), but 55% now call the sector "fairly valued" and only 22% see it as undervalued, down from 52% just six months earlier. The share calling it overvalued jumped from 6% to 23%. Their historical work found only three prior times in a decade when the XBI beat the S&P by 15%+ in a short window, and forward returns afterward were "more mixed." RBC's bottom line: the second half "is going to reward selectivity more than it rewards breadth."

Is the M&A wave ending? RBC thinks we may be "in the later innings of this particular M&A cycle." The natural buyers, "Vertex, Gilead, AbbVie, Biogen, Neurocrine," have either done their deals or need time to digest, targets have gotten pricier, and it is harder to pay a premium on a stock that already prices in a takeout. But the structural driver hasn't gone away: RBC estimates ~$400 billion in large-pharma revenue is at risk from patent expirations over the next decade, against $180+ billion in aggregate annual free cash flow big pharma can spend buying replacements. One tantalizing note: investors' second-most-likely predicted catalyst was a $20B+ acquisition, and an AstraZeneca to Bristol-Myers Squibb "mega merger" was floated in the press, though RBC's own US pharma analyst Trung Nguyen "thinks there's a low probability of this deal happening."

Do the drug-pricing deals actually help patients, and will they last? Steve Usdin's contrarian read on BioCentury: the deals are structured so they "don't inflict a great deal of pain on the companies" and "probably don't result in major savings for the taxpayers." His warning: if Democrats take a chamber of Congress in the midterms, "one of the first things they're going to do is subpoena the companies" to expose the deals, which could ironically "drive Congress to try to impose more stringent price controls." The deeper divide he framed is generational: are you optimizing prices on drugs that already exist, or preserving incentives to invent future drugs? He argued applying international reference pricing mainly to Medicaid "sends a signal that companies and investors are going to prefer to develop drugs that aren't primarily for the Medicaid population," hard to call good for patients.

Do cancer vaccines actually work? A genuinely two-sided week. Merck and Moderna reported a positive Phase 3 melanoma-vaccine result (their shot paired with Keytruda), which UBS's Michael Yee flagged as a real Merck catalyst. But on Telltales, the hosts noted BioNTech just ended a Phase 2 colorectal-cancer vaccine after seeing "no net effect." Their synthesis: these vaccines seem to work only in combination with an immunotherapy like Keytruda, and only in cancers that are already "visible" to the immune system, not as a standalone or in immune-cold tumors. The episode also flagged a detail investors sometimes miss: Moderna splits Keytruda-combo cancer-vaccine economics 50-50 with Merck under a pre-COVID deal, hence the episode title, "Moderna Only Owns Half of Its Own Cancer Vaccine."

Is AI drug discovery real or hype? The Inceptive/Alnylam conversation was the bull case, but even its own CEO conceded that generic AI can't cut it: the useful expertise "is incredibly vertical specific... there's no way a company of 40 to 50 people like Inceptive could figure out which problems are the right problems" alone. The honest version of the bull case is "AI plus a proven biology platform plus deep pharma partners," not "AI alone."

3. Stock by stock: bull vs. bear

Eli Lilly (LLY), Bull (CEO David Ricks / BioCentury): The obesity franchise is early (25 to 30M patients out of 1B+ potential), being made "more durable" via next-gen drugs (retatrutide, aluralintide) and an oral pill, while 13 acquisitions this year diversify beyond GLP-1. On the employer-coverage worry (PepsiCo and others dropping coverage), Ricks argued net demand is "about flat" and that a Lilly study showed ZepBound was "more than break even" by month 12. Bear/risk: Employers balking at cost; a spending pace ($31.5B on deals YTD) that assumes many bets pay off; "not all these bets will play off" (his words).

Merck (MRK), Bull (UBS's Michael Yee): "We've been super bullish on Merck." The Moderna cancer-vaccine win is "just one of seven things across Merck's portfolio," plus a new chemo/ADC cancer drug coming later this year, transforming "the old sleepy pharma with the big patent cliff" into a growth story with "multiple expansion." Bear: That very patent cliff, Keytruda's ~$30B in annual sales losing US exclusivity, is the single biggest overhang in pharma (per the Elon Musk Podcast explainer).

Revolution Medicine (RVMD/"RevMed"), Bull (Michael Yee): Its breakthrough pancreatic-cancer drug just got a fast FDA approval, and "that continues to put a big day in lung cancer... we've really just been early in where the potential is." Also flagged on BioSpace (RevMed's pancreatic-cancer approval) and OncoPharm (daraxonrasib in lung cancer).

Bristol-Myers Squibb (BMY), Bull (Michael Yee): "Another big one," playing in both cancer vaccines and the same growth areas as Merck. Bear (Elon Musk Podcast): Facing a "severe concentration challenge," Opdivo and Eliquis (~$14B, ~30% of revenue) expiring together, "over 65% revenue exposure."

Gilead Sciences (GILD), Bull (Tony Zhang on In the Money): One of the strongest big-pharma names, breaking above $140 toward ~$150 all-time highs, with a path to $157+. The HIV franchise is growing "nearly 40% year-over-year," oncology "nearly 25%." The 46x forward P/E is misleading, distorted by a ~$4B non-cash acquisition charge; on a cleaner basis it trades "at a discount relative to its peers" despite being "nearly three times as profitable as its industry." Average Wall Street price target ~$158, with some recent buy ratings at $170 to 180. Bear: The stock has already had "a decent run," so upside may be limited near-term (he chose a more conservative options structure to reflect that).

Medtronic (MDT), Bull (CEO Jeff Martha on Squawk on the Street): A record Q1 with a top- and bottom-line beat, cardio sales up over 19% year-on-year, raised outlook, and a $700 million investment into robotic-surgery firm Cornerstone Robotics. Growth drivers: afib ablation, robotics, hypertension, plus the core pacemaker/defibrillator and spine businesses. Two years of "tuck-in M&A" have "doubled our investment in innovation," and the stock has outperformed peers including Boston Scientific (BSX) and Stryker. Martha's analogy for AI in surgery: "a driver-assist kind of technology... helping surgeons, not replacing them." Bear/risk: Headwinds Martha named himself, cybersecurity attacks across medtech (Boston Scientific, Stryker, Medtronic all hit), tariffs, inflation, and supply-chain strain.

Moderna (MRNA) & BioNTech (BNTX), Mixed (Telltales): Moderna's melanoma vaccine is a real win but shared 50-50 with Merck; BioNTech's colorectal vaccine failed in Phase 2. Cancer vaccines are a "combination-only, immune-hot-tumors-only" story for now.

Danaher (DHR), Bull (Lean Focus, via former Radiometer CEO Peter Kürstein): A rare inside look at the "Danaher Business System." Radiometer had a 35% global market share and 23% operating margins before Danaher; under DBS, an infamous exercise found a product with "18 days of lead time and only 24 minutes of actual value-added work," and the operating discipline that followed took margins from 23% to 33%. A window into why Danaher is the benchmark operator in life-science tools.

AstraZeneca (AZN), Neutral/pipeline: Heart-failure candidate AZD5462 (Luminara) and Enhertu/TDXd (with Daiichi Sankyo) in breast cancer both featured, mixed but scientifically interesting readouts (Circulation, Breast Cancer Update). Also the subject of unconfirmed BMS-merger speculation (RBC assigns low odds).

Small-cap catalyst name, BioCorRx (BICX): On Seth Farbman's podcast, CEO Lourdes Felix described a formerly pre-revenue addiction-treatment company: lead product BICX-104 (a 3-month naltrexone implant) plus a newly acquired FDA-approved revenue asset, Lucemyra, for opioid withdrawal. Micro-cap and speculative, flagged for awareness, not endorsement.

4. Notable quotes

  • Michael Yee, UBS pharma & biotech analyst (Closing Bell): "The charts are starting to break out. People are paying attention and they sort of have to... because the sector is breaking out. And I think that we're going to move higher because people are appreciating this and the valuations are not expensive." He also called biotech "a bit of the anti-AI trade."
  • Brian Abrams, RBC head of global healthcare research (Pathfinders): "The XBI is up 80% in the past year, and a lot of that has come since early June... When you look at what's driven it, you really have to start with M&A."
  • Lisa Walter, RBC (Pathfinders), on the sentiment shift: "55% of investors now see biotech as fairly valued... Only 22% still see the sector as undervalued, which is down from 52% at our last check-in six months ago."
  • Steve Usdin, BioCentury, on the pricing deals: "When they do [become public], what people are going to see is that deals are structured in a way in which they don't inflict a great deal of pain on the companies. They probably don't result in major savings for the taxpayers."
  • David Ricks, Eli Lilly CEO (Squawk on the Street), to employers dropping coverage: "You're already paying for obesity, whether you cover the drugs or not... treating it is a smarter play."
  • Howard Lutnick, Commerce Secretary (Balance of Power): "Build it here and you won't pay a tariff while you're building. But if you're not willing to put shovels in the ground here, then you should pay to have access to the greatest market in the world."
  • On the patent cliff (Elon Musk Podcast): "Over $500 billion in projected annual global drug sales... are about to lose their exclusive patent protection... We are talking about half of all currently marketed drugs legally losing their monopolies in the coming years."
  • Jakob Uszkoreit, Inceptive CEO (Inside the ICE House): "AI's lifeblood is data. And it's not just a little data... you need a ton, and you need data that speaks to the problems that you're trying to solve."
  • Jeff Martha, Medtronic CEO (Squawk on the Street): "The innovation is outpacing that [tariffs, cyber, inflation]... And we're not just [taking] market share, we're actually growing the markets."

5. Catalysts to watch

  • Medicare MFN demonstrations (CMMI): BioCentury's Usdin expects announcements "in the coming weeks or months" on applying most-favored-nation pricing to Medicare Part B and Part D, the "hammer" behind the pricing deals, and likely to trigger industry litigation. Watch: all large/mid pharma.
  • The midterm elections: A Democratic win in either chamber could reopen the drug-pricing fight (subpoenas of the MFN deals, a push toward international reference pricing for Medicare negotiation). Also historically a seasonal M&A catalyst.
  • More Lilly deals & the oral GLP-1 (Foundeo) ramp: Given 13 takeouts YTD, another "manic Monday" deal is a base case; watch oral-pill uptake and the Medicare Bridge program. (LLY)
  • Merck's late-2026 catalysts: New chemo/ADC cancer drug launch plus continued Moderna cancer-vaccine progress, the crux of the "Merck as growth company" thesis. (MRK, MRNA)
  • RevMed's expansion from pancreatic into lung cancer. (RVMD)
  • Section 232 pharma tariffs set to take effect in September (with generics tariffs phased in over a few years), watch which companies remain exempt via US-build + MFN commitments.
  • Possible $20B+ M&A / AZN to BMS chatter: RBC's investors flagged a mega-deal as a top predicted catalyst; RBC's own analyst rates the specific AZN to BMS combination low-probability. (AZN, BMY)
  • The 13th China Healthcare Summit (Nov 2 to 4, Shanghai): referenced as the venue where the "China biotech" debate will play out, a topic notably thin in this week's episodes.

6. Coverage gaps

Coverage this week was strong on the biotech rally, drug pricing, Lilly/obesity, and the patent cliff, but thin or absent in a few areas the strategy usually tracks:

  • GLP-1 challengers (Viking/VKTX, Altimmune/ALT, Zealand/ZEAL): No standalone investor episodes this week. The obesity conversation was dominated by Lilly (and, to a lesser extent, Novo Nordisk via the patent-cliff discussion of Ozempic). No CagriSema-vs-orforglipron head-to-head and no direct Lilly-vs-Novo competitive debate surfaced.
  • China biotech: Discussed only in passing (a BMS-context mention and a conference plug). No dedicated "is the China threat existential or manageable" episode.
  • Life-science tools / CROs (Thermo Fisher, IQVIA, ICON, Charles River, Agilent): The only real tools content was the Danaher/Radiometer operating story; no earnings-driven CRO commentary.
  • CDMO capacity / manufacturing reshoring specifics: Plenty of general tariff/reshoring talk, but little pharma-specific CDMO analysis with named companies.
  • Named sell-side pharma analysts: Aside from UBS's Michael Yee and the RBC team, no other individual bank analysts (JPM, Morgan Stanley, Goldman pharma desks) appeared within the 7-day window.